Alexion has announced that four members of the company’s C-suite team are set to leave the company, following an internal investigation into sales practices.
Chief financial officer Dave Anderson is among the casualties, who while just joining the company this past December is set to resign in August. Alexion will also lose its R&D chief, Martin Mackay, to retirement. EVP and head of human resources Clare Carmichael and commercial chief Carsten Thiel are leaving as well, with Thiel’s replacement, Brian Goff, already hired.
Alexion has completely remade its executive makeup, which began when former CEO David Hallal lost investor confidence amid sales fraud investigations that demonstrated that the company inappropriately pressured staff to pad sales of its Soliris treatment.
> Read the Wall Street Journal report
Source: Pharmaceutical Manufacturing
The deal inked with New York-based Ovid Therapeutics carries an almost $200 million upfront payment and could be worth as much as $856 million provided the medicine, known as soticlestat, hits certain milestones.
Novartis has entered an initial agreement to manufacture the mRNA and bulk drug product for CureVac’s Covid-19 vaccine candidate, CVnCoV.
A whole new world: Philips and the Walt Disney Company will use animated shorts featuring some of Disney’s most famous characters in customized stories created with clinical guidance from Philips.
